## Tick-Borne Encephalitis Vaccine (TBE)

| Vaccine Description | • TICOVAC™  
|                     | • Inactivated  
|                     | • Contains human serum albumin  
|                     | • See package insert  |

### Dose & Route
- **Dose**: 0.5 mL  
- **Route**: IM (Use IM precautions for persons with bleeding disorders or receiving anticoagulant therapy)

### Indications
- Individuals 16 years and older to prevent tick-borne encephalitis.  
- Recommended for people who are living or traveling overseas to a tick-borne encephalitis (TBE) endemic area and will extensive exposure to ticks based on their planned outdoor activities and itinerary.

### Administration Schedule
- 3 doses at 0, 14 days -- 3 months, 5-12 months.  
- Complete the primary immunization series at least 1 week prior to potential exposure to tick-borne encephalitis virus (TBEV)

<table>
<thead>
<tr>
<th>Dose</th>
<th>Dose Recommended Interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Day 0</td>
</tr>
<tr>
<td>2</td>
<td>14 days-3 months after first vaccination</td>
</tr>
<tr>
<td>3</td>
<td>5-12 months after second vaccination</td>
</tr>
</tbody>
</table>

### Booster
- 4th dose may be given at least 3 years after completion of primary immunization series if ongoing exposure or re-exposure to TBEV is expected

### Contraindications
- Severe allergic reaction (e.g. anaphylaxis) to any component of TICOVAC™
Precautions

- Some individuals with altered immunocompetence may have reduced immune response
- Vaccination with TICOVAC™ may not protect all individuals
- There are no adequate and well-controlled studies of TICOVAC™ in pregnant women.
- Clinical studies did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects

Special Considerations

- Bring vaccine to room temperature before administration. Shake well prior to administration to thoroughly mix the vaccine suspension. After shaking, the vaccine should be a homogenous off-white, opalescent suspension. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not administer if particulate matter or discoloration remains after shaking.

VIS: Currently a VIS is not available from the CDC, patient education material available at [www.health.mil/tbe](http://www.health.mil/tbe). When VIS becomes available it will be provided to all patients prior to vaccination.